Novavax, Inc. (NASDAQ:NVAX)’s share price gapped down prior to trading on Friday . The stock had previously closed at $1.21, but opened at $1.18. Novavax shares last traded at $1.14, with a volume of 4,656,074 shares traded.

NVAX has been the subject of a number of recent research reports. BidaskClub cut Novavax from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Zacks Investment Research cut Novavax from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Ladenburg Thalmann Financial Services raised Novavax from a “neutral” rating to a “buy” rating and set a $1.60 target price for the company in a report on Wednesday, August 9th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 target price on shares of Novavax in a report on Friday, July 21st. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $1.50 target price on shares of Novavax in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $3.05.

The firm’s 50 day moving average is $1.14 and its 200 day moving average is $1.07. The company’s market capitalization is $330.49 million.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.15 million. During the same quarter in the previous year, the business earned ($0.29) EPS. Novavax’s revenue was up 168.0% compared to the same quarter last year. Equities analysts expect that Novavax, Inc. will post ($0.62) EPS for the current year.

In related news, Director James F. Young sold 175,000 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $1.06, for a total transaction of $185,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.00% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. increased its holdings in Novavax by 49.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 29,800 shares during the period. Profund Advisors LLC increased its holdings in Novavax by 0.4% during the 2nd quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 455 shares during the period. Voya Investment Management LLC increased its holdings in Novavax by 18.6% during the 2nd quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 21,639 shares during the period. HighTower Advisors LLC increased its holdings in Novavax by 3.8% during the 1st quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 5,250 shares during the period. Finally, American International Group Inc. increased its holdings in Novavax by 7.1% during the 1st quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 10,965 shares during the period. Institutional investors own 45.17% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Novavax, Inc. (NVAX) Shares Gap Down to $1.18” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/novavax-inc-nvax-shares-gap-down-to-1-18/1629042.html.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.